Prospects for gene therapy in corneal disease
1Cornea and External Disease Service, Moorfields Eye Hospital, London, UK.
Abstract:
Transfer of cDNA to corneal cells has been accomplished using viral and nonviral vectors. Studies examining the feasibility and optimal methods for vector-mediated gene transfer to the cornea have, as in other tissues, been performed using histochemical or fluorescent marker genes. These have used corneal cells or cell lines in vitro, and whole corneas maintained in ex vivo culture. Gene-based interventions have been examined in specific corneal disorders such as allograft rejection, postexcimer laser scarring, and herpes simplex keratitis using experimental models. As the feasibility of genetic modification of corneal cells has been successfully demonstrated, there is great potential for gene therapy vectors in the treatment of human corneal disease. Continued improvements in vectors for gene transfer will improve the efficacy and safety of gene therapy. In addition to use of cDNA transfer as an alternative to drug or protein treatments in acquired corneal disorders, our expanding knowledge of the genetic basis of inherited corneal disorders will ultimately lead to the development of specific and effective gene therapies in this category of diseases.
Insights
Gene therapy using viral and nonviral vectors successfully transfers cDNA to corneal cells. This demonstrates significant potential for treating corneal diseases, both acquired and inherited, through genetic modification.
Area of Science:
- Ophthalmology
- Gene Therapy
- Molecular Biology
Background:
- Gene transfer to corneal cells is crucial for developing novel treatments for corneal diseases.
- Viral and nonviral vectors are established methods for delivering genetic material.
- Previous studies utilized marker genes to assess gene transfer efficiency in corneal models.
Purpose of the Study:
- To review the feasibility and methods of vector-mediated gene transfer to corneal cells.
- To highlight the potential of gene therapy for various corneal disorders.
- To discuss the future development of gene therapies for inherited corneal conditions.
Main Methods:
- Utilized viral and nonviral vectors for cDNA transfer into corneal cells.
- Employed histochemical or fluorescent marker genes to evaluate gene transfer efficiency.
- Conducted studies in vitro using corneal cells/cell lines and ex vivo using whole corneas.
- Examined gene-based interventions in experimental models of corneal diseases.
Main Results:
- Successfully demonstrated the feasibility of genetic modification of corneal cells.
- Established vector-mediated gene transfer as a viable approach for corneal applications.
- Identified potential applications in treating allograft rejection, postexcimer laser scarring, and herpes simplex keratitis.
Conclusions:
- Gene therapy vectors hold great promise for treating human corneal diseases.
- Improvements in vector technology will enhance the efficacy and safety of corneal gene therapy.
- Gene therapy offers a potential alternative to traditional treatments and a future for inherited corneal disorders.
